<DOC>
	<DOCNO>NCT02055066</DOCNO>
	<brief_summary>This first-in-human study antibody block function oncogene c-met patient cancer .</brief_summary>
	<brief_title>A Phase 1b Study ARGX-111 Patients With Advanced Cancer .</brief_title>
	<detailed_description>This Phase 1b trial characterize safety profile ARGX 111 thus provide first element towards establish accurate risk-benefit assessment ARGX 111 cancer patient .</detailed_description>
	<criteria>1 . Written informed consent . 2 . Age ≥ 18 year . 3 . Performance status 0 1 . 4 . Histological diagnosis malignancy . 5 . Cancer relapsing , refractory standard therapy . 6 . Malignancy overexpressing c Met protein . 7 . Presence circulate tumor cell ( CTCs ) . 8 . At least one tumor lesion &gt; 2 cm PET/CT . 9 . Serum albumin &gt; 35 g/L . 10 . Absolute neutrophil count ( ANC ) &gt; 1.0 x 109/L . 11 . Hemoglobin &gt; 90 g/L ( 0.9 g/dL ) . 12 . Platelet count ≥ 75 x 109/L . 13 . Coagulation parameter ≤ 1.5 x ULN . 14 . Total bilirubin ≤ 1.5 x upper limit normal ( ULN ) . 15 . Creatine Phosphokinase ( CPK ) ≤ 2.5 x ULN . 16 . Serum creatinine ≤ 1.5 x ULN . 17 . Ability comply protocolspecified procedures/evaluations schedule visit . 1 . History clinical evidence neoplastic central nervous system ( CNS ) involvement . 2 . Major surgery within 4 week ARGX 111 first dose administration . 3 . Systemic glucocorticoid administration dose great physiological replacement ( prednisone 20 mg equivalent ) within 3 week ARGX 111 first dose administration . 4 . Cytotoxic chemotherapy within 3 week ARGX 111 first dose administration . 5 . Radiation therapy curative intent within 3 week ARGX 111 first dose administration . 6 . Biological therapy ( monoclonal antibody ) within 4 week ARGX 111 first dose administration . 7 . Biological therapy ( monoclonal antibody ) within 5 halflives ARGX 111 first dose administration . 8 . Unresolved Grade 3 4 toxicity prior therapy , include experimental therapy . 9 . History recurrent Grade 3 4 toxicity anti c Met therapy . 10 . Uncontrolled diabetes , define fast glycemia &gt; 150 mg/dl ) . 11 . Active , untreated viral , bacterial , systemic fungal infection . 12 . Any clinical finding , include psychiatric behavioral problem , , opinion Investigator , preclude patient safely participate study . 13 . Childbearing potential ( unless use adequate measure contraception ) . 14 . Pregnancy lactation . 15 . History severe ( Grade 3 4 ) hypersensitivity recombinant protein .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>cancer</keyword>
	<keyword>c-MET</keyword>
</DOC>